keyword
MENU ▼
Read by QxMD icon Read
search

Jan burger

keyword
https://www.readbyqxmd.com/read/27924711/occupational-risk-factors-for-relapse-free-survival-in-bladder-cancer-patients
#1
Silvia Selinski, Hannah Bürger, Meinolf Blaszkewicz, Thomas Otto, Frank Volkert, Oliver Moormann, Hartmut Niedner, Jan G Hengstler, Klaus Golka
The influence of occupational risk factors on bladder cancer development is well investigated. However, studies on the influence on bladder cancer prognosis are rare. Therefore, it was of interest to investigate the time to first relapse in the follow-ups of three case-control series from Dortmund, Neuss, and Lutherstadt Wittenberg, Germany. Relapse-free survival of in total 794 urinary bladder cancer patients (Dortmund 174, Neuss 407, Lutherstadt Wittenberg 213) was derived from medical records. Cox regression models were used to determine the impact of profession and exposure to bladder carcinogens if the risk factor was present in at least four cases...
2016: Journal of Toxicology and Environmental Health. Part A
https://www.readbyqxmd.com/read/27924709/occupational-risk-factors-for-prostate-cancer-in-an-area-of-former-coal-iron-and-steel-industries-in-germany-part-2-results-from-a-study-performed-in-the-1990s
#2
Sabina Krech, Silvia Selinski, Hannah Bürger, Jan G Hengstler, Peter Jedrusik, Jasmin Hodzic, H-Jürgen Knopf, Klaus Golka
Currently, there is no established occupational risk factor for prostate cancer. However, in the 1980s, a hospital-based case-control study in the greater Dortmund area showed an elevated risk for hard coal miners and, based on few cases, for painters and varnishers. Therefore, approximately 10 yr later, a similar study regarding prostate cancer was performed in this area. In total, 292 patients with prostate cancer who underwent radical prostatectomy and 313 controls who underwent transurethral resection of a benign prostatic hyperplasia were investigated by questionnaire...
2016: Journal of Toxicology and Environmental Health. Part A
https://www.readbyqxmd.com/read/27919243/tumour-stage-distribution-and-survival-of-malignant-melanoma-in-germany-2002-2011
#3
Olaf Schoffer, Stefanie Schülein, Gerlinde Arand, Hans Arnholdt, Dieter Baaske, Ralf C Bargou, Nikolaus Becker, Matthias W Beckmann, Yves Bodack, Beatrix Böhme, Tayfun Bozkurt, Regine Breitsprecher, Andre Buchali, Elke Burger, Ulrike Burger, Klaus Dommisch, Gudrun Elsner, Karin Fernschild, Ulrike Flintzer, Uwe Funke, Michael Gerken, Hubert Göbel, Norbert Grobe, Vera Gumpp, Lucie Heinzerling, Lana Raffaela Kempfer, Alexander Kiani, Monika Klinkhammer-Schalke, Sabine Klöcking, Ute Kreibich, Katrin Knabner, Peter Kuhn, Stine Lutze, Uwe Mäder, Tanja Maisel, Jan Maschke, Martin Middeke, Andreas Neubauer, Antje Niedostatek, Anabelle Opazo-Saez, Christoph Peters, Beatrice Schell, Gerhard Schenkirsch, Harald Schmalenberg, Peter Schmidt, Constanze Schneider, Birgit Schubotz, Anika Seide, Paul Strecker, Sabine Taubenheim, Matthias Wackes, Steffen Weiß, Claudia Welke, Carmen Werner, Christian Wittekind, Jörg Wulff, Heike Zettl, Stefanie J Klug
BACKGROUND: Over the past two decades, there has been a rising trend in malignant melanoma incidence worldwide. In 2008, Germany introduced a nationwide skin cancer screening program starting at age 35. The aims of this study were to analyse the distribution of malignant melanoma tumour stages over time, as well as demographic and regional differences in stage distribution and survival of melanoma patients. METHODS: Pooled data from 61 895 malignant melanoma patients diagnosed between 2002 and 2011 and documented in 28 German population-based and hospital-based clinical cancer registries were analysed using descriptive methods, joinpoint regression, logistic regression and relative survival...
December 5, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27897414/a-comparative-study-of-software-programmes-for-cross-sectional-skeletal-muscle-and-adipose-tissue-measurements-on-abdominal-computed-tomography-scans-of-rectal-cancer-patients
#4
Jeroen L A van Vugt, Stef Levolger, Arvind Gharbharan, Marcel Koek, Wiro J Niessen, Jacobus W A Burger, Sten P Willemsen, Ron W F de Bruin, Jan N M IJzermans
BACKGROUND: The association between body composition (e.g. sarcopenia or visceral obesity) and treatment outcomes, such as survival, using single-slice computed tomography (CT)-based measurements has recently been studied in various patient groups. These studies have been conducted with different software programmes, each with their specific characteristics, of which the inter-observer, intra-observer, and inter-software correlation are unknown. Therefore, a comparative study was performed...
November 22, 2016: Journal of Cachexia, Sarcopenia and Muscle
https://www.readbyqxmd.com/read/27797975/long-term-follow-up-of-treatment-with-ibrutinib-and-rituximab-ir-in-patients-with-high-risk-chronic-lymphocytic-leukemia-cll
#5
Preetesh Jain, Michael J Keating, William Wierda, Mariela Sivina, Philip A Thompson, Alessandra Ferrajoli, Zeev Estrov, Hagop Kantarjian, Susan O'Brien, Jan Burger
BACKGROUND: Ibrutinib is an active therapy with acceptable safety profile for patients with CLL, including high-risk patients with del17p or with TP53 mutations. Ibrutinib is broadly indicated for the treatment of patients with chronic lymphocytic leukemia and specifically including those with 17p deletion. The optimal use of ibrutinib in combination with other agents, remains controversial. METHODS: We report the long term outcome [median follow up of 47 months (range 36-51 months)] of 40 patients with high risk CLL, treated on the first ibrutinib combination trial with rituximab (IR)...
October 19, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27786334/cd70-limits-atherosclerosis-and-promotes-macrophage-function
#6
Holger Winkels, Svenja Meiler, Esther Smeets, Dirk Lievens, David Engel, Charlotte Spitz, Christina Bürger, Petteri Rinne, Linda Beckers, Angelika Dandl, Sigrid Reim, Maiwand Ahmadsei, Jan Van den Bossche, Lesca M Holdt, Remco T A Megens, Martin Schmitt, Menno de Winther, Eric A Biessen, Jannie Borst, Alexander Faussner, Christian Weber, Esther Lutgens, Norbert Gerdes
The co-stimulatory molecule CD70 is expressed on activated immune cells and is known to modulate responses of T, B, and NK cells via its receptor CD27. Until now, there is only limited data describing the role of CD70 in atherosclerosis. We observed that ruptured human carotid atherosclerotic plaques displayed higher CD70 expression than stable carotid atherosclerotic plaques, and that CD70 expression in murine atheroma localized to macrophages. Lack of CD70 impaired the inflammatory capacity (e. g. reactive oxygen species and nitric oxide production) of bone marrow-derived macrophages, increased both M1-like and M2-like macrophage markers, and rendered macrophages metabolically inactive and prone to apoptosis...
October 27, 2016: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/27765613/the-use-of-neoadjuvant-chemotherapy-in-patients-with-urothelial-carcinoma-of-the-bladder-current-practice-among-clinicians
#7
Thomas Martini, Christian Gilfrich, Roman Mayr, Maximilian Burger, Armin Pycha, Atiqullah Aziz, Michael Gierth, Christian G Stief, Stefan C Müller, Florian Wagenlehner, Jan Roigas, Oliver W Hakenberg, Florian Roghmann, Philipp Nuhn, Manfred Wirth, Vladimir Novotny, Boris Hadaschik, Marc-Oliver Grimm, Paul Schramek, Axel Haferkamp, Daniela Colleselli, Birgit Kloss, Edwin Herrmann, Margit Fisch, Matthias May, Christian Bolenz
INTRODUCTION: Guidelines recommend neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) in patients with urothelial carcinoma of the bladder in clinical stages T2-T4a, cN0M0. We examined the frequency and current practice of NAC and sought to identify predictors for the use of NAC in a prospective contemporary cohort. MATERIALS AND METHODS: We analyzed prospective data from 679 patients in the PROMETRICS (PROspective MulticEnTer RadIcal Cystectomy Series 2011) database...
September 19, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27754477/early-cave-art-and-ancient-dna-record-the-origin-of-european-bison
#8
Julien Soubrier, Graham Gower, Kefei Chen, Stephen M Richards, Bastien Llamas, Kieren J Mitchell, Simon Y W Ho, Pavel Kosintsev, Michael S Y Lee, Gennady Baryshnikov, Ruth Bollongino, Pere Bover, Joachim Burger, David Chivall, Evelyne Crégut-Bonnoure, Jared E Decker, Vladimir B Doronichev, Katerina Douka, Damien A Fordham, Federica Fontana, Carole Fritz, Jan Glimmerveen, Liubov V Golovanova, Colin Groves, Antonio Guerreschi, Wolfgang Haak, Tom Higham, Emilia Hofman-Kamińska, Alexander Immel, Marie-Anne Julien, Johannes Krause, Oleksandra Krotova, Frauke Langbein, Greger Larson, Adam Rohrlach, Amelie Scheu, Robert D Schnabel, Jeremy F Taylor, Małgorzata Tokarska, Gilles Tosello, Johannes van der Plicht, Ayla van Loenen, Jean-Denis Vigne, Oliver Wooley, Ludovic Orlando, Rafał Kowalczyk, Beth Shapiro, Alan Cooper
The two living species of bison (European and American) are among the few terrestrial megafauna to have survived the late Pleistocene extinctions. Despite the extensive bovid fossil record in Eurasia, the evolutionary history of the European bison (or wisent, Bison bonasus) before the Holocene (<11.7 thousand years ago (kya)) remains a mystery. We use complete ancient mitochondrial genomes and genome-wide nuclear DNA surveys to reveal that the wisent is the product of hybridization between the extinct steppe bison (Bison priscus) and ancestors of modern cattle (aurochs, Bos primigenius) before 120 kya, and contains up to 10% aurochs genomic ancestry...
October 18, 2016: Nature Communications
https://www.readbyqxmd.com/read/27742770/inhibition-of-demethylase-kdm6b-sensitizes-diffuse-large-b-cell-lymphoma-to-chemotherapeutic-drugs
#9
Rohit Mathur, Lalit Sehgal, Ondrej Havranek, Stefan Köhrer, Tamer Khashab, Neeraj Jain, Jan A Burger, Sattva S Neelapu, R Eric Davis, Felipe Samaniego
Histone methylation and demethylation regulates B-cell development, and their deregulation correlates with tumor chemoresistance in diffuse large B-cell lymphoma, limiting curative rates. Since histone methylation status correlates with disease aggressiveness and relapse, we investigated the therapeutic potential of inhibiting histone 3 Lys27 demethylase KDM6B, in-vitro, using the small molecule inhibitor GSK-J4. KDM6B is overexpressed in the DLBCL germinal center B-cell subtype, and higher KDM6B levels are associated with worse survival in DLBCL patients treated with R-CHOP...
October 14, 2016: Haematologica
https://www.readbyqxmd.com/read/27697994/the-dual-syk-jak-inhibitor-cerdulatinib-antagonises-b-cell-receptor-and-microenvironmental-signaling-in-chronic-lymphocytic-leukemia
#10
Matthew D Blunt, Stefan Koehrer, Rachel Dobson, Marta Larrayoz, Sarah Wilmore, Alice Hayman, Jack Parnell, Lindsay D Smith, Andrew Davies, Peter Wm Johnson, Pamela B Conley, Anjali Pandey, Jonathan C Strefford, Freda K Stevenson, Graham Packham, Francesco Forconi, Greg P Coffey, Jan Burger, Andrew J Steele
PURPOSE: B-cell receptor (BCR)-associated kinase inhibitors such as ibrutinib have revolutionised the treatment of chronic lymphocytic leukemia (CLL). However, these agents are not curative and resistance is already emerging in a proportion of patients. Interleukin-4 (IL-4), expressed in CLL lymph nodes, can augment BCR-signalling and reduce the effectiveness of BCR-kinase inhibitors. Therefore simultaneous targeting of the IL-4- and BCR-signalling pathways by cerdulatinib, a novel dual Syk/JAK inhibitor currently in clinical trials (NCT01994382), may improve treatment responses in patients...
October 3, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27673440/buparlisib-a-pi3k-inhibitor-demonstrates-acceptable-tolerability-and-preliminary-activity-in-a-phase-i-trial-of-patients-with-advanced-leukemias
#11
Brittany Knick Ragon, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Jorge Cortes, Gautam Borthakur, LaKiesha DeBose, Zhihong Zeng, Heather Schneider, Naveen Pemmaraju, Guillermo Garcia-Manero, Steven Kornblau, William Wierda, Jan Burger, Courtney D DiNardo, Michael Andreeff, Marina Konopleva, Naval Daver
Phosphatidylinositol-3-kinase (PI3K) signaling plays a crucial role in oncogene-mediated tumor growth and proliferation. Buparlisib (BKM120) is an oral pan-class I PI3K inhibitor. This phase I study was conducted to determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of BKM120 in patients (pts) with relapsed/refractory acute leukemias. Fourteen pts (12 acute myeloid leukemia, 1 acute lymphoblastic leukemia, 1 mixed phenotype leukemia) were enrolled. Twelve pts received BKM-120 80 mg/day and two 100 mg/day...
September 27, 2016: American Journal of Hematology
https://www.readbyqxmd.com/read/27619383/about-the-nanostructure-of-the-ternary-system-water-bmim-pf6-tx-100
#12
Harun Bilgili, Matthias Bürger, Cosima Stubenrauch, Jan H Porada
HYPOTHESIS: Many efforts have been made to formulate water-IL microemulsions. One of the most intensely studied systems is H2O - 1-butyl-3-methylimidazolium hexafluorophosphate ([BMIm]PF6) - 4-octylphenol polyethoxylate (TX-100) and it is not questioned that this system forms microemulsions. The nanostructures observed for traditional microemulsions are postulated with the surfactant being adsorbed at the interface such that the hydrophilic EO sides intrude into the water domains, while the hydrophobic hydrocarbon chains are immersed into [BMIm]PF6...
December 15, 2016: Journal of Colloid and Interface Science
https://www.readbyqxmd.com/read/27602755/ibrutinib-modifies-the-function-of-monocyte-macrophage-population-in-chronic-lymphocytic-leukemia
#13
Stefania Fiorcari, Rossana Maffei, Valentina Audrito, Silvia Martinelli, Elisa Ten Hacken, Patrizia Zucchini, Giulia Grisendi, Leonardo Potenza, Mario Luppi, Jan A Burger, Silvia Deaglio, Roberto Marasca
In lymphoid organs, nurse-like cells (NLCs) show properties of tumor-associated macrophages, playing a crucial role in chronic lymphocytic leukemia (CLL) cell survival. Ibrutinib, a potent inhibitor of Bruton's tyrosine kinase (BTK), is able to counteract pro-survival signals in CLL cells. Since the effects on CLL cells have been studied in the last years, less is known about the influence of ibrutinib on NLCs properties. We sought to determine how ibrutinib modifies NLCs functions focusing on the balance between immunosuppressive and inflammatory features...
September 1, 2016: Oncotarget
https://www.readbyqxmd.com/read/27576248/a-multiple-label-guided-clustering-algorithm-for-historical-document-dating-and-localization
#14
Sheng He, Petros Samara, Jan Burgers, Lambert Schomaker
It is of essential importance for historians to know the date and place of origin of the documents they study. It would be a huge advancement for historical scholars if it would be possible to automatically estimate the geographical and temporal provenance of a handwritten document by inferring them from the handwriting style of such a document. We propose a multiple-label guided clustering algorithm to discover the correlations between the concrete low-level visual elements in historical documents and abstract labels, such as date and location...
November 2016: IEEE Transactions on Image Processing: a Publication of the IEEE Signal Processing Society
https://www.readbyqxmd.com/read/27534555/functional-differences-between-igm-and-igd-signaling-in-chronic-lymphocytic-leukemia
#15
Elisa Ten Hacken, Mariela Sivina, Ekaterina Kim, Susan O'Brien, William G Wierda, Alessandra Ferrajoli, Zeev Estrov, Michael J Keating, Thomas Oellerich, Cristina Scielzo, Paolo Ghia, Federico Caligaris-Cappio, Jan A Burger
BCR signaling is a central pathogenetic pathway in chronic lymphocytic leukemia (CLL). Most CLL cells express BCRs of IgM and IgD isotypes, but the contribution of these isotypes to functional responses remains incompletely defined. We therefore investigated differences between IgM and IgD signaling in freshly isolated peripheral blood CLL cells and in CLL cells cultured with nurselike cells, a model that mimics the lymph node microenvironment. IgM signaling induced prolonged activation of ERK kinases and promoted CLL cell survival, CCL3 and CCL4 chemokine secretion, and downregulation of BCL6, the transcriptional repressor of CCL3 In contrast, IgD signaling induced activation of the cytoskeletal protein HS1, along with F-actin polymerization, which resulted in rapid receptor internalization and failure to support downstream responses, including CLL cell survival and chemokine secretion...
September 15, 2016: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/27462702/oncological-outcomes-of-patients-with-concomitant-bladder-and-urethral-carcinoma
#16
Georgios Gakis, Jason A Efstathiou, Siamak Daneshmand, Kirk A Keegan, Rebecca H Clayman, Jan Hrbacek, Bedeir Ali-El-Dein, Harras B Zaid, Tina Schubert, Johannes Mischinger, Tilman Todenhöfer, Sigolene Galland, Kola Olugbade, Michael Rink, Hans-Martin Fritsche, Maximilian Burger, Sam S Chang, Marko Babjuk, George N Thalmann, Arnulf Stenzl, Todd M Morgan
INTRODUCTION: The study aimed to investigate oncological outcomes of patients with concomitant bladder cancer (BC) and urethral carcinoma. METHODS: This is a multicenter series of 110 patients (74 men, 36 women) diagnosed with urethral carcinoma at 10 referral centers between 1993 and 2012. Kaplan-Meier analysis was used to investigate the impact of BC on survival, and Cox regression multivariable analysis was performed to identify predictors of recurrence. RESULTS: Synchronous BC was diagnosed in 13 (12%) patients, and the median follow-up was 21 months (interquartile range 4-48)...
2016: Urologia Internationalis
https://www.readbyqxmd.com/read/27317921/diffusion-tensor-imaging-in-euthymic-bipolar-disorder-a-tract-based-spatial-statistics-study
#17
Bartholomeus C M 'Benno' Haarman, Rixt F Riemersma-Van der Lek, Huibert Burger, Jan Cees de Groot, Hemmo A Drexhage, Willem A Nolen, Leonardo Cerliani
BACKGROUND: In the current DTI study we compared euthymic bipolar I disorder (BD-I) patients and healthy controls (HC). We subsequently divided the total patient group into lithium-users and non-lithium-users and estimated differences across the three groups. METHODS: Twenty-one euthymic BD-I patients and twenty-two HC participants were included in psychiatric interviews and MRI image acquisition (diffusion-weighted (DW) and T1-weighted scans). Fractional anisotropy (FA), radial, mean and axial diffusivity (RD, MD, AD) were estimated from the DW data, using DTI...
October 2016: Journal of Affective Disorders
https://www.readbyqxmd.com/read/27311765/corrigendum-to-volume-metabolites-and-neuroinflammation-of-the-hippocampus-in-bipolar-disorder-a-combined-magnetic-resonance-imaging-and-positron-emission-tomography-study-brain-behav-immun-2015
#18
Bartholomeus C M 'Benno' Haarman, Huibert Burger, Janine Doorduin, Remco J Renken, Anita J Sibeijn-Kuiper, Jan-Bernard C Marsman, Erik F J de Vries, Jan Cees de Groot, Hemmo A Drexhage, Richard Mendes, Willem A Nolen, Rixt F Riemersma-Van der Lek
No abstract text is available yet for this article.
June 13, 2016: Brain, Behavior, and Immunity
https://www.readbyqxmd.com/read/27301277/long-term-durable-remission-by-cladribine-followed-by-rituximab-in-patients-with-hairy-cell-leukaemia-update-of-a-phase-ii-trial
#19
Dai Chihara, Hagop Kantarjian, Susan O'Brien, Jeffrey Jorgensen, Sherry Pierce, Stefan Faderl, Alessandra Ferrajoli, Rebecca Poku, Preetesh Jain, Phillip Thompson, Mark Brandt, Rajyalakshmi Luthra, Jan Burger, Michael Keating, Farhad Ravandi
Nucleoside analogues are highly active in patients with hairy cell leukaemia (HCL); however, patients continue to relapse. This phase II study evaluated the efficacy and safety of cladribine followed by rituximab in patients with untreated HCL (N = 59), relapsed HCL (N = 14) and HCL variant (HCLv, N = 7). Cladribine 5·6 mg/m(2) was given intravenously (IV) daily for 5 d and was followed approximately 1 month later with rituximab 375 mg/m(2) IV weekly for 8 weeks. Complete response rate in patients with untreated HCL, relapsed HCL and HCLv was 100%, 100% and 86%, respectively...
September 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27283218/comparative-analysis-of-the-effect-of-prostatic-invasion-patterns-on-cancer-specific-mortality-after-radical-cystectomy-in-pt4a-urothelial-carcinoma-of-the-bladder
#20
Stefan Vallo, Christian Gilfrich, Maximilian Burger, Björn Volkmer, Katharina Boehm, Michael Rink, Felix K Chun, Florian Roghmann, Vladimir Novotny, Jens Mani, Antonin Brisuda, Roman Mayr, Regina Stredele, Joachim Noldus, Marco Schnabel, Matthias May, Hans-Martin Fritsche, Armin Pycha, Thomas Martini, Manfred Wirth, Jan Roigas, Patrick J Bastian, Philipp Nuhn, Roland Dahlem, Axel Haferkamp, Margit Fisch, Atiqullah Aziz
PURPOSE: To evaluate the prognostic relevance of different prostatic invasion patterns in pT4a urothelial carcinoma of the bladder (UCB) after radical cystectomy. MATERIALS AND METHODS: Our study comprised a total of 358 men with pT4a UCB. Patients were divided in 2 groups-group A with stromal infiltration of the prostate via the prostatic urethra with additional muscle-invasive UCB (n = 121, 33.8%) and group B with continuous infiltration of the prostate through the entire bladder wall (n = 237, 66...
October 2016: Urologic Oncology
keyword
keyword
30230
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"